Enzyme Inhibitors: Recent Advances in the Anticancer Research
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 307
Special Issue Editors
Interests: medicinal chemistry; drug discovery; aromatase inhibitors; PPAR ligands; anticancer agents
Special Issues, Collections and Topics in MDPI journals
Interests: drug discovery; computational techniques; anticancer agents; aromatase inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The success of modulating enzyme activity as a strategy for drug development is evidenced by the fact that over 50% of commercially available drugs are composed of small molecules active on enzymes.
The involvement of enzymes in the critical stages of a disease's development makes them an ideal biological target for the design of molecules capable of docking sensitive ligand-binding sites.
Different enzymes are involved in the multiple pathogenetic mechanisms of cancer and, in recent years, there has been continuous progress in the development of therapeutic agents against the disease, including the identification of novel enzymatic targets and their inhibitors.
In this Special Issue, we focus our attention on new target-based anticancer agents that inhibit a specific enzyme involved in the development of cancer and in the control of chemoresistance.
We welcome the submission of research and review articles on the advances in the drug discovery, design, and development of enzyme inhibitors effective against various cancer models. Covered topics include the synthesis of novel compounds, the repurposing of old drugs, the use of natural compounds and drug metabolites, biological studies, and computational approaches.
This Special Issue aims to summarize the state of the art and the latest findings in the identification of suitable anticancer enzyme inhibitors, and to elucidate future directions.
Dr. Alessandra Ammazzalorso
Dr. Marialuigia Fantacuzzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer drugs
- cancer therapy
- drug discovery
- enzyme inhibitor
- synthesis
- structure–activity relationships
- natural compounds
